The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II- III heart failure

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 8, 2008, Pages 389-399

  Harjola, Veli Pekka ^a   Oikarinen, L ^a   Toivonen, L ^a   Jurkko, R ^a   Puttonen, J ^b   Sarapohja, T ^b   Sundberg, S ^b   Nieminen, M S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Inter actions; Levosimendan; Magnetocardiography; Repolarization; Systolic time interval

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LEVOSIMENDAN; PLACEBO; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIGOXIN BLOOD LEVEL; DISEASE CLASSIFICATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; ELECTROCARDIOGRAM; ERYTHROCYTE; FEMALE; HEADACHE; HEART FAILURE; HEART PALPITATION; HEART RATE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; INOTROPISM; MAGNETOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 48749114001     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp46389     Document Type: Article

References (42)

1. Antila S, Honkanen T, Lehtonen L, Neuvonen PJ. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug, levosimendan. Int J Clin Pharmacol Ther. 1998; 36: 446-449.
2. Antila S, Huuskonen H, Nevalainen T, Kanerva H, Vanninen P, Lehtonen L. Site-dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci. 1999; 9: 85-91.
3. Antila S, Kivikko M, Lehtonen L, Eha J, Heikkila A, Pohjanjousi P, Pentikainen PJ. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol. 2004a; 57: 412-415.
4. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, Scheinin H. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci. 2004b; 23: 213-222.
5. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm. 2005; 2: 9-15.
6. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of β-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006; 20: 273-282.
7. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24: 442-463.
8. de Mey C, Belz GG, Nixdorf U, Butzer R, Schroeter V, Meyer J, Erbel R. Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers. Clin Pharmacol Ther. 1992; 52: 609-619.
9. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IP. Cardiac troponin C as a target protein for a novel calcium-sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995; 27: 1859-1866.
10. Haikala H, Kaheinen P, Levijoki J, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997; 34: 536-546.
11. Harjola VP, Peuhkurinen K, Nieminen MS. Niemela M, Sundberg S. Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol. 1999; 83: 4(I)-8(I).
12. Hirata S, Izumi S, Furukubo T, Ota M, Fujita M, Yamakawa T, Hasegawa I, Ohtani H, Sawada Y. Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int J Clin Pharmacol Ther. 2005; 43: 30-36.
13. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005; 78: 260-277.
14. Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol. 2003; 55: 544-551.
15. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002a; 42: 43-51.
16. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002b; 40: 465-471.
17. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003; 107: 81-86.
18. Kristof E, Szigeti G, Papp Z, Bodi A, Facsko A, Kovacs L, Papp JG, Kranias EG, Edes I. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann N Y Acad Sci. 1998; 853: 316-319.
19. Lant J, Stroink G, ten Voorde B, Horacek BM, Montague TJ. Complementary nature of electrocardiographic and magnetocardiographic data in patients with ischemic heart disease. J Electrocardiol. 1990; 23: 315-322.
20. Li Q, Belz GG. Systolic time intervals in clinical pharmacology. Eur J Clin Pharmacol. 1993; 44: 415-421.
21. Martin CE, Shaver JA, Thompson ME, Reddy PS, Leonard JJ. Direct correlation of external systolic time intervals with internal indices of left ventricular function in man. Circulation. 1971; 44: 419-431.
22. Nakamura Y, Wiegner AW, Gaasch WH, Bing OH. Systolic time intervals: assessment by isolated cardiac muscle studies. J Am Coll Cardiol. 1983; 2: 973-978.
23. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36: 1903-1912.
24. Oikarinen L, Paavola M, Montonen J, Viitasalo M, Makijarvi M, Toivonen L, Katila T. Magnetocardiographic QT interval dispersion in postmyocardial infarction patients with sustained ventricular tachycardia: validation of automated QT measurements. Pacing Clin Electrophysiol. 1998a; 21: 1934-1942.
25. Oikarinen L, Viitasalo M, Toivonen L. Dispersions of the QT interval in postmyocardial infarction patients presenting with ventricular tachycardia or with ventricular fibrillation. Am J Cardiol. 1998b; 81: 694-697.
26. Oikarinen L, Viitasalo M, Korhonen P, Vaananen H, Hanninen H, Montonen J, Makijarvi M, Katila T, Toivonen L. Postmyocardial infarction patients susceptible to ventricular tachycardia show increased T wave dispersion independent of delayed ventricular conduction. J Cardiovasc Electrophysiol. 2001; 12: 1115-1120.
27. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology. 1994; 81: 974-987.
28. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000; 52: 213-217.
29. Poder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, Lehtonen L. Pharmacodynamics and pharmcokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol. 2004; 44. 1143-1150.
30. 2- sensitizer, levosimendan, to recombinant human cardiac troponin C. J Biol Chem. 1994; 269: 28584-28590.
31. Puttonen J, Kantele S, Kivikko M, Hakkinen S, Harjola VP, Koskinen P, Pentikainen PJ. Effect of severe renal failure and hemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007; 46: 235-246.
32. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350: 1013-1022.
33. Rowland M, Tozer T. Distribution kinetics. In: Clinical Pharmacokinetics, Concepts and Applications (3rd ed). Baltimore, USA; Williams and Wilkins; 1995. p. 313-339.
34. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000; 102: 2222-2227.
35. Sundberg S. Short- and long-term variation of systolic and diastolic time intervals at rest and during dynamic exercise in healthy subjects. Am J Noninvas Cardiol. 1993; 7: 301-305.
36. Takahashi R, Talukder MA, Endoh M. Effects of OR-1896. an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol. 2000a; 36: 118-125.
37. Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol. 2000b; 400: 103-112.
38. Udvary E, Papp JG, Vegh A. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Br J Pharmacol. 1995; 114: 656-661.
39. Weissler AM, Harris WS, Schoenfeld CD. Systolic time intervals in heart failure in man. Circulation. 1968; 37: 149-159.
40. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 1998; 98: 1928-1936.
41. + channel in rat arterial myocytes. Eur J Pharmacol. 1997; 333: 249-259.
42. Zabel M, Portnoy S, Franz MR. Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol. 1995; 25: 746-752.